Hiroshi Nagabukuro

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.

SMBC Venture Capital KK (SMBC Venture Capital) is a Private Equity firm, a subsidiary of Sumitomo Mitsui Banking Corp., itself a subsidiary of publicly traded company Sumitomo Mitsui Financial Group, Inc. (TK:8316) founded in 2005. The firm is headquartered in Tokyo.

Whiz Partners, Inc. (Whiz Partners) is an independent venture capital firm headquartered in Tokyo, Japan. It became a separate entity from its former brand, CSK Venture Capital Co., Ltd. The firm was founded by Toshio Ando, Atsushi Matsumura, and Junichi Kajimoto in 2010.

Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto.

CellAxia, Inc. is a Japanese company that engages in research and development, manufacturing, and selling of pharmaceutical products. The company is based in Tokyo, Japan. The company was founded in 2017 by Makoto Seki.

Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom.

RBG Partners KK engages in the operation and management of investment business partnership assets. It also deals with the acquisition and holding of securities and offers consulting services for company diagnosis and investment planning. The company was founded on October 2, 2018 and is headquartered in Yokohama, Japan.

IgniteEye Corp. engages in the provision of cloud services for recruitment activities. Its cloud products include SONAR, Compass, Sniping and CREATIVE. The company was founded by Takashi Yoshida in May 2013 and is headquartered in Tokyo, Japan.

Axcelead Drug Discovery Partners, Inc. is a Japanese company founded in 2017 that provides services for the quality evaluation of new modality regenerative medical cells, effectiveness and safety evaluation of target cells, and bridging data. The company is based in Fujisawa, JP. and has subsidiaries in the United States. It is used by more than 100 facilities such as clients pharmaceutical companies, venture companies, and academia. Axcelead offers non-clinical development strategic planning and problem resolution services to its clients.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.